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ABSTRACT 
 This research project focused on the differences observed in muscle fiber 
composition and surface area between wild type mice and Ames dwarf mice as they aged. 
A mouse model was utilized because the skeletal muscle framework of mice closely 
resembles that of human muscle; thus, the observations seen within the mice may also be 
seen within humans as they age. Comparisons between the wild type and dwarf mice 
include a smaller cross-sectional muscle area in a dwarf mouse and no drastic change in 
the percentages of fast and slow twitch muscle fibers as the dwarf mouse ages. 
Furthermore, differences in fiber length and cross-sectional muscle area between wild 
type and dwarf mice were revealed. However, exact conclusions on muscle fiber 
composition and surface area as mice age cannot be drawn secondary to the limited 
number of lower extremity musculature that was obtained. Current knowledge of 
sarcopenia and its effects were also explored throughout this paper.  
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CHAPTER I 
INTRODUCTION AND LITERATURE REVIEW 
 Sarcopenia has become increasingly prevalent in the population secondary to 
increased longevity of life seen in communities. It is expected that sarcopenia will 
continue to steadily escalate in the population as the anticipated life expectancy rises; 
furthermore, the population of adults aged 65 and over will double within the next 15 
years.1 With these projected outcomes, age-related losses in skeletal muscle mass and 
function will become a crucial aspect in the provided health services. These functional 
declines can contribute to the increased hospitalizations secondary to falls and subsequent 
hip fractures; hence, there may be an increased prevalence of gait disorders and balance 
disturbances in the elderly. Currently, the term sarcopenia is being used interchangeably 
with loss of muscle mass, strength, and function. Loss of muscle mass and strength, 
cognitive decline, and a decrease in overall physical functioning are associated with the 
aging process. The loss of muscle mass and strength can occur as early as the third 
decade of life but is most commonly seen in the fourth decade and beyond.2,3 However, 
there is conflicting evidence surrounding the age at which cognitive decline begins. Some 
researchers argue cognitive decline starts in the sixth decade of life; whereas, others have 
suggested it can appear as early as the second or third decade.4 
Research has proposed decreased participation in physical activity leads to the 
gradual loss of muscle mass (atrophy); however, several other factors may also contribute 
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to loss of strength and muscular atrophy.  Clinically relevant questions center on how to 
define sarcopenia. Once sarcopenia is defined, how does one medically treat it and are 
there therapeutic rehabilitative approaches? Are there ways to prevent sarcopenia? The 
following paragraphs will aim to answer these questions. Furthermore, the meaningful 
role that Ames dwarf mice play in sarcopenia research will be discussed.  
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CHAPTER II 
RESEARCH DESCRIPTION 
 Research’s efforts have revealed that by the time a person reaches the age of 50, 
there is an average decline of 1% to 2% of muscle mass per year. By age 80, a person’s 
muscle mass decline has reached approximately 50%. Once muscle mass falls below two 
standard deviations of the mean of a standardized young control group and gait speed 
declines to 0.8 m/s2, a clinical diagnosis of sarcopenia is concluded. It is estimated that 
5% to 13% of persons aged 60 to 70 years are affected by this disorder; this percentage 
increases to 11% to 50% for persons aged 80 years and older.5 Another group of 
researchers conclude that females aged 75 years and older lose approximately 0.64% to 
0.7% in muscle mass per year; whereas, males aged 75 years and older tend to lose 0.8% 
to 0.98% per year. Furthermore, the loss of muscular strength is considered to be 2 to 5 
times greater than the loss of muscle mass.3 Advanced skeletal muscle loss may affect a 
person’s quality of life, the need for support services, and eventually long term care.6 
This loss of muscular strength is a consistent risk factor for the development of 
disabilities associated with sarcopenia.3 Ultimately, the ability to climb stairs, ambulate, 
maintain proper balance and posture, and transfer from sit to stand will become 
increasingly strenuous and difficult. 
 Experimental research using molecular genetics has revealed several 
pathophysiological disturbances that occur with sarcopenia. Molecular genetics seeks to 
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identify alterations in protein arrangements and the effects these alterations have on the 
organism. In the molecular genetics research of sarcopenia, there have been several 
discoveries which have aided in establishing further research projects and a more broad-
base of knowledge in muscle tissue proteomics.  These discoveries include the 
association of age-dependent muscular wasting with impaired muscle protein synthesis, 
impaired metabolic pathways, disrupted ion homeostasis, unbalanced levels of growth 
factors and hormones, excitation and muscular contraction uncoupling, reduced cellular 
stress response, heightened susceptibility to apoptosis, and diminished regenerative 
capacity.7 Through the use of molecular genetics and proteomics, sarcopenia is now more 
accurately defined.   
What is sarcopenia and how it is classified? 
 Researchers have created several possible definitions for sarcopenia. One 
definition states that decreased muscle strength, (which was represented by knee 
extension isometric torque in this study), handgrip strength, lower extremity muscle 
power, and physical performance measured by gait speed are indicative of sarcopenia. 
Another definition states muscle strength or function has a direct correlation with muscle 
mass; therefore, if muscle mass decreases, it can be assumed that the strength of the 
muscle would also diminish. For example, one with low muscle mass would most likely 
have a decreased gait speed secondary to the reduced amount of muscular power 
produced by muscles. Muscular power is lost before muscular strength. Muscle power is 
defined as the ability to generate as much force as quickly as possible; whereas, strength 
is defined as the ability to generate as much force as possible under no time constraints. 
Mathematically, power is calculated by dividing work by time; strength is calculated by 
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multiplying the mass and distance it has traveled (or work it has done).  While both 
muscle power and strength are important for functional daily activities, power is better at 
predicting the ease in which functional activities are performed; thus, a person who has 
decreased gait speed more than likely has a decreased ability to generate adequate muscle 
power to efficiently contract his lower extremity muscles to move in a forward 
progression.2,8 
However, different researchers have argued the term sarcopenia describes 
alterations in muscle structure, function, and body composition which lead to weakness 
and dysfunction. At the time, the term was mainly used as a major determinant in the 
decline of physical function and seen as a risk factor for disability and disease.  Other 
early definitions include any type of muscle loss due to disease, any person who required 
the use of an assistive device, and any person who has had a history of falls.9  
In 1998, researchers began developing methods of classification and diagnostic 
criteria for sarcopenia; these are still utilized in determining the severity of the disease.  
Sarcopenia classification began with using mathematical formulas.  Different 
mathematical formulas have been suggested to define the rate of sarcopenia. One formula 
demonstrates sarcopenia as appendicular skeletal mass (ASM), which is the sum of lean 
mass for both arms and legs, divided by the height squared (kg/m2).2,10 Values that were 
at least two standard deviations below the mean of a reference population were classified 
as having sarcopenia. Another formula that was introduced used muscle mass; this 
formula corrected muscle mass for a combination of height, fat mass, or total body mass.2 
Formulas used to compute this percentage included ASM (kg) = 0.2487 (weight) + 
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0.0483(height) -0.1584(hip circumference) + 0.0732(grip strength) +2.5843(sex) + 
5.8828 for determination of muscle mass and percentage of body fat = 0.2034(waist 
circumference) + 0.2288(hip circumference) + 3.6827(In triceps skinfold)- 10.9814(sex) - 
14.3341.10 The latter formula was derived using the bioelectrical impedance analysis 
(BIA) equation which was cross-validated with magnetic resonance imaging (MRI) 
measures of whole body muscle mass and body mass index. This particular study found a 
correlation of 0.93 and a 9.0% standard error of the estimate between MRI and the BIA 
equation. From this study, absolute muscle mass in kilograms (kg), was normalized for 
height and termed skeletal muscle index (SMI).11 These formulas have been utilized to 
generate criteria to diagnose sarcopenia.  
Diagnostic criteria correlate to the understanding of related consequences low 
muscle mass has on a person’s ability to execute daily and vocational functions. Evidence 
has shown muscle mass is associated with a person’s self-reported physical disability and 
functional impairments.2 It has been recently suggested the main criteria for sarcopenia 
diagnosis include low muscle mass greater than two standard deviations below the mean, 
low muscle strength, diminished physical performance, and gait speed less than 0.8m/s2.5 
Contributing factors to this diagnosis are chronic inflammation, reduced protein intake, 
motor neuron atrophy, and immobility.12  
Physicians are now classifying sarcopenia by severity using SMI. In order to 
determine “normal” skeletal muscle mass, SMI values were obtained from young persons 
aged 18 to 39 years old. Classification criteria for sarcopenia were derived using the SMI 
values from the young population.6 Class I sarcopenia is defined as SMI that is between 
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one and two standard deviations below the young adult values; it is most commonly 
associated with increased difficulty in stooping, crouching, kneeling, and ability to 
perform tandem stance. Class II sarcopenia is SMI that is greater than two standard 
deviations below the young adult values; it is most commonly associated with increased 
difficulty in climbing 10 stairs, lifting/carrying 10 pounds, rising to a stand from a chair, 
and decreased ability to perform household chores. A normal SMI is considered to be 
within one standard deviation of the gender-specific mean for young adults. The 
researchers utilized this approach because it was considered comparable to the use of 
bone mineral density of a young reference group for classifying normal bone density, 
osteopenia, and osteoporosis. It was discovered the prevalence of class I and class II 
sarcopenia increased from the third to sixth decades, but remained relatively constant in 
the seventh decade and beyond.6,9 Sarcopenia classification can be further aided by a 
physician’s prescription for diagnostic imaging.  
Imaging is also routinely performed in the diagnosis of sarcopenia; the most 
common imaging techniques include MRI, dual energy X-ray absorptiometry (DEXA), 
and bioelectrical impedance analysis (BIA). MRIs allow the radiologist to determine 
segmental and total muscle mass, and assess overall muscle quality through calculating 
fat infiltration in muscle. DEXA has the advantage of analyzing body composition and is 
currently used as the procedure of choice for bone mineral density. BIA is currently 
recognized as the most specific exam to assess lean muscle mass and body fat. It is a 
routine exam that assesses body composition by focusing in on the molecular level, as a 
representation of the amount of muscle mass.12 It measures tissue resistance through an 
electrical signal to determine the proportion of body fat to lean mass.  This calculation is 
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done as the signal’s current easily flows through parts of the body that are composed 
mainly of water such as blood, urine, and muscle.13 This technique is a reliable analysis 
in the study for lean mass versus muscle mass. BIA has several advantages including no 
radiation exposure, relatively inexpensive, requires no specialized staff, and is a portable 
machine; hence, the test can be completed at the patient’s bedside.12 In a study done by 
Janssen and colleagues, they revealed that the BIA has greater precision in classifying 
class II sarcopenia and estimating the percentage of skeletal muscle mass than the other 
aforementioned methods.6 Sarcopenia classification is accomplished through utilizing 
SMI young adult values attained through previous research. Type I sarcopenia is defined 
as SMI that is between one and two standard deviations below the young adult values and 
type II is classified as being greater than two standard deviations compared to young 
adult values.6  In another study, researchers concluded BIA using vector analysis was 
sensitive in determining body mass differences; however, it was not as sensitive in the 
assessing specific features of a person’s body composition. Furthermore, they discovered 
BIA could also be used in determining nutritional status in the elderly secondary to the 
ability to recognize individuals with different quantities of absolute mass. They 
concluded this newer technique of utilizing vector analysis may be applicable in finding 
several age-related conditions including sarcopenia and sarcopenic obesity.14  
Now that there is an understanding of how sarcopenia is classified and diagnosed, 
it is important to recognize how the muscle fiber and motor unit is structured, how much 
energy/power is required for muscle contraction, and how functional impairments occur 
as the muscle motor unit ages. Power for a muscular contraction occurs within the actin 
and myosin components of the sarcomere. Myosin plays an important role as it aids in the 
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differentiation of motor unit subtypes. Three motor unit types exist: slow oxidative, fast-
fatigable, and fast fatigue-resistant motor units. In general, slow oxidative motor units 
have the smallest number of muscle fibers and are principally composed of type I myosin. 
These motor units will contract with slow velocity and are usually recruited for fine 
motor activities and gravity opposition. Unique characteristics of fast-fatigable motor 
units are high numbers of muscular fibers and the large cross-sectional areas. 
Additionally, they have the highest contractile velocity and are composed mainly of type 
IIb fibers, (now known as IIx in humans), and myosin, which transfer energy at a much 
higher rate than slow motor units.   Any activity that requires a maximal power 
generation, such as weight-lifting or sprinting, will recruit fast-fatigable motor units. Fast 
fatigue-resistant motor units are composed of type I, type IIa, and type IIb muscle fibers. 
Transfer of energy occurs at a slower rate than fast-fatigable motor units, but faster than 
slow oxidative motor units.1 
Several aging processes can result in alterations in mass, composition, contractile 
properties, and mechanical properties of skeletal muscle tissue. One such process is the 
loss of slow and fast motor units and atrophy of muscle fibers as described above. 
Denervation of motor units result in this loss; in order to compensate, the remaining 
motor units will convert the denervated fiber type to that of the motor unit. Consequently, 
type II fast-fatigable fibers are converted into slow type I fibers.1  This transition of fast-
to- slow muscle fibers is apparent with physical exercise, low-frequency stimulation, 
hyper-excitability, and aging; these effects are most commonly seen in sarcopenic muscle. 
Researchers have suggested these muscle fiber transitions are most likely caused by a 
secondary occurrence. They are a result of faulty reinnervation mechanisms post 
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denervation, apoptosis-triggered loss of spinal motor neurons, and selective atrophy of 
type II fibers.  
In contrast, slow-to-fast muscle fiber transitions (type I to type II) are commonly 
associated with disuse atrophy, extensive bed rest, and microgravity.7 Muscular atrophy 
is characterized by a reduction in muscle fiber cross-sectional area, sarcomere dissolution, 
decreased mitochondria, and greater amounts of connective tissue within the muscle.  
Type I muscle fibers are the first to atrophy; type II fibers will start to atrophy later. 
Researchers suggest this finding is secondary to the extensive use of type I fibers; the 
majority of muscular contractions recruit type I fibers before type II fibers.  Hence, it 
would be logical that with muscular atrophy, type I fibers lose their primary 
characteristics and begin to imitate the characteristics of type II fibers.15 The loss of both 
type I and type II fibers accelerates age-related alterations in muscle function. This 
progression of muscle function degenerative modification develops as muscle fibers 
undergo a shift from anaerobic-oxidative metabolism to aerobic-oxidative metabolism.  
Aerobic-oxidative metabolism shifts have been researched through proteomics, 
the study of protein structures and functions. Emerging scientific research aims to 
observe ongoing intercellular transformations as the proteome is subjected to variable 
environments. Thus far, proteomic profiling has established extensive adjustments made 
in the expression patterns of specific proteins in aging skeletal muscle. These adjustments 
include enzymatic metabolic pathways, elements of the cellular stress response, and ion 
homeostasis regulatory components. One finding discovered that pyruvate kinase, a rate-
limiting glycolytic enzyme, is significantly reduced in aged skeletal muscle; however, 
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essential mitochondrial proteins are amplified in sarcopenia. This discovery proposed a 
shift from anaerobic-oxidative to aerobic-oxidative metabolism, hence, altering the way 
in which muscle fibers respond to physical stressors.  
The role of Ames dwarf mice 
Numerous studies have been conducted on the protein arrangement of muscle 
fibers as they age. Comparisons between human skeletal muscle and mouse skeletal 
muscle are most common because the skeletal muscle in mice closely resembles that of 
human skeletal muscle. Since mice are frequently used for experimental research, these 
experiments are easily performed and provide a wealth of knowledge surrounding this 
particular diagnosis.16  
Several mouse models, Ames dwarf mice included, carry specific genetic 
mutations which are associated with increased life span. Additionally, they have 
diminished levels of mitochondria and endogenous reactive oxygen species (ROS), and 
an increased resistance to oxidative stress. These mutations are beneficial in mediating 
longevity, thus extending their lifespan. Researchers have hypothesized that ROS-
mediated oxidative damage is an essential component in determining longevity. They 
suggest that these physiological characteristics of mitochondrial function are developed 
early in life and continue throughout the life cycle. Moreover, Ames dwarf mice also 
have unique hormonal characteristics; they lack growth hormone (GH), thyroid 
stimulating hormone (TSH), and prolactin. Ames Dwarf mice persistently live 
approximately 40%-60% longer than their normal littermates.17  
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Previous studies have also compared genetic versus environmental influences in 
the progression of sarcopenia. A group of researchers led by Edstrom detected the 
importance of metabolism and extent of muscle usage as the mouse aged.18 To determine 
the role of metabolism within the aging process, a litter of mice were put on restricted 
diets.  The results of dietary restriction revealed a reduction in the appearance of several 
characteristic features in aging skeletal muscle through the restoration of transcriptional 
alterations that naturally occur with the aging process. Activity and exercise 
demonstrated similar results. Increasing levels of activity help maintain the current 
strength of muscle mass, thus, reversing the detrimental effects of aging on skeletal 
muscle.  
For this research project, the lower extremity musculature of Ames dwarf mice 
was analyzed. The muscle tissues that were removed from the mice were placed on liver 
tissue to maintain resting length on a stable surface. The goal was to determine the 
number of fast-glycolytic and slow-oxidative muscle fiber cells located within the soleus 
(SOL) and extensor digitorum longus (EDL) muscles.  Ames dwarf mice have a point 
mutation on chromosome 11 and characteristically have primary pituitary hormonal 
deficiency caused by reduced anterior pituitary cells. These cells produce and secrete 
prolactin, thyroid stimulating hormone (TSH), and growth hormone (GH). It has been 
suggested that these hormonal deficiencies play an important role in the longevity of 
Ames dwarf mice; in the cases of TSH and GH deficits, the lifespan may be influenced 
by lower metabolic rates and reduced premature aging. Furthermore, their small body 
size may also impact survival.19,20 Previous research has demonstrated significant 
differences in cardiac, liver, and kidney tissues between dwarf mice and normal mice; 
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these differences have been linked to life longevity, enzyme metabolism, and the absence 
of anterior pituitary hormones. Because Ames dwarf mice exhibit substantial tissue 
variances, current research is now asking, how does muscle tissue vary between wild type 
and dwarf mice and does it reveal aerobic-oxidative metabolic shifts or conversion of 
type II to type I muscle fibers? Does the delayed aging seen in Ames dwarf mice avoid 
the sarcopenic effects in muscle? If it does, how would this discovery contribute to the 
research in muscle health in humans? This was the area of focus in this research study. It 
aimed to detect differences in muscle fibers as they age. Observations of cross-sectional 
muscle area and fiber type composition of age-matched mice (3 month, 6 month and 12 
month old) were analyzed and comparisons across ages were obtained.  
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CHAPTER III 
METHODS 
Muscle tissues were obtained from both wild type and Ames dwarf mice. Four 
muscles were extracted from bilateral lower extremities including SOL, gastrocnemius-
plantaris (GP), EDL, and tibialis anterior (TA).  After the muscles were extracted, they 
were placed on a slice of liver tissue that was surgically removed from a wild type mouse.   
Skeletal Muscle Tissue Acquisition 
Tribromoethanol, (2.5% in 0.9% saline per 100 µl/10g body weight) – [~300 µl – 
400 µl for wild type mouse], was injected intraperitoneally to anesthetize the animals. 
Once the injection was given, the mouse’s pain and corneal reflexes were checked every 
couple minutes; when the mouse no longer responded to the stimuli, surgery proceeded.   
Low angle cuts were made around the legs and ankles in order to free hind limb 
skin. The skin was detached from the muscles by inserting a scissors underneath the skin 
and spreading the scissors open to pull the skin away from the surrounding tissues. Cuts 
were made up the skin proximally towards the hip and the skin was peeled away. The 
distal attachment of the GP and SOL was severed by slicing the tendon at the heel. SOL 
was separated from the GP musculature at the knee joint; it was then cut at the knee and 
retracted towards the distal end. Another cut was made to remove the SOL. The tissue 
was then placed on a piece of liver, covered with Optimal Cutting Temperature (OCT) 
compound, and then frozen in isopentane in liquid nitrogen. Next, GP was removed from 
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its attachment at the knee. Following the above procedure, the tissue was then frozen in 
isopentane in liquid nitrogen. The third muscle extracted was the TA. Fascia surrounding 
TA was removed by toothed forceps; TA was freed by sliding the instrument along the 
tibia. The TA tendon was severed at both the ankle and knee. Again, the same freezing 
procedure as the GP was utilized. Finally, the EDL was located, removed from its 
attachments at the ankle and knee, and frozen in the same manner as the SOL. 
Slicing Muscle Tissue 
 Muscle tissue was sliced using a Cryostat which was cooled to -25˚C (optimal 
cutting temperature) for 8 to 10 hours.  The cutting blade was rinsed with alcohol, 
inserted in to the Cryostat, and allowed to cool for 30 minutes. Tissue samples were 
refrigerated at -80˚C; hence, they needed to warm up to -25˚C prior to slicing. Once the 
appropriate temperature had been reached, the muscle tissue was set vertically on a metal 
plate with OCT to secure the sample. Slicing was done in 50-µm sections (trim) until 
arriving at the muscle tissue. The blade was then switched to 10-µm sections (fine). Fifty 
10-µm sections were sliced to attain the main portion of the muscle. After reaching the 
main muscular portion, 10-µm serial sections were collected and placed on slides. The 
slides used for collection were Fisher Superfrost Plus Microscope slides (Fisher Scientific 
Pittsburgh, PA. Cat. No. 12-550-15 for 25 x 75 x 1.0 mm). Three sections were placed on 
each slide. When thirty sections had been compiled, another fifty 10-µm sections were 
skipped. Next, an additional 30 sections of 10-µm was recovered and placed on slides. 
This procedure was repeated until the end of the muscle was reached.  The slides 
containing muscle tissue were then stored in a refrigerator at -20˚C.  
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Hematoxylin And Eosin Staining 
 The slides were submerged in Harris hematoxylin for two minutes and then rinsed 
in distilled water twice. Next, the stained slides were transferred to acid alcohol (11 ml 
glacial acetic acid, 95 ml ethanol, and 5 ml distilled water) and dipped three times. Again, 
they were rinsed in distilled water. The slides were then dipped in ammonium water 
(0.588 ml of 28% NH4OH in 250 ml dH2O) six times and rinsed with distilled water. A 
working solution of eosin was mixed; it consisted of 100 ml stock eosin, 300 ml 80% 
ethanol, and 2.5 ml glacial acetic acid. The slides remained in the working solution for 
thirty seconds. Afterwards, the slides were rinsed twice in distilled water. Finally, the 
slides were dehydrated, for 15 seconds each, in 75%, 95%, and 100% ethanol and clear 
xylene. Once dehydrated, the slides were mounted with Permount and stored at room 
temperature.  
Immunohistochemistry For Mouse Myosin Heavy Chains 
 Tissue slides were removed from the freezer and allowed to warm-up to room 
temperature. While the slides were warming, a working 1x phosphate buffered saline 
(PBS) solution was prepared. The solution was diluted with distilled water and potassium 
chloride to achieve a pH of 7.4. This solution was used throughout the procedure for 
rinsing the slides in between cellular staining. A total of 18 slides were stained; 8 slides 
were stained with fast-twitch, 8 with slow-twitch, and 2 were the control group.  
 Once the slides achieved room temperature, the tissue samples were encircled 
using a PAP pen and then rinsed in 1X PBS for 2 minutes. PAP pens are used for 
applying immunohistochemistry to slides; the hydrophobic properties of the pen allow 
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the user to draw barriers on a slide to confine the applied reagents to a defined area. The 
encircled area has a visible blue/green marking. For immunohistochemistry, the PAP pen 
should be applied following deparaffinization. A series of protein and blocking solutions 
were applied to the tissue samples, slides were incubated, and then rinsed in 1X PBS.  
First, a mixed solution of 30% hydrogen peroxide and horse serum (30 µl H2O2 + 9 µl 
horse serum in 3 ml PBS) was added to the tissues and then incubated for 5 minutes. 
Slides were then rinsed in PBS solution twice for 2 minutes. Avidin blocking solution 
was allotted for 15 minutes; a 2 minute rinsing in PBS solution followed. Next, biotin 
blocking solution was placed on the samples for 15 minutes and then the samples were 
rinsed for 2 minutes in PBS. The slides were then incubated and covered for 60 minutes 
with a mixture consisting of 36 µl mouse IgG blocking reagent and 1 ml PBS. 
Subsequently, the tissues were rinsed in PBS twice for 2 minutes.  
Thereafter, mouse on mouse concentrate (M.O.M.), which is a combination of 
160 µl of protein concentrate and 2 ml PBS, was placed on the slides and allowed to sit 
for 5 minutes. Slides were then stained with either a fast-twitch or slow-twitch protein; 
456 µl of M.O.M. diluent + 24 µl of slow antibody protein was added to 8 tissues slides 
and 425 µl of M.O.M. diluent + 47 µl of fast antibody protein was placed on another 8 
tissue slides.  These slides were incubated in 100 µl of primary antibody dilution and 
covered for 30 minutes. During the time of incubation, a solution of 1.25 ml of PBS, 1 
drop of reagent A and 1 drop of reagent B was prepared and allowed to stand at room 
temperature for 30 minutes.  
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 After the slides were rinsed in PBS solution twice for 2 minutes, they were 
incubated in 4 µl of M.O.M. biotinylated anti-mouse IgG reagent and 1 ml M.O.M. 
working diluent for 10 minutes. Again, slides were rinsed in PBS for 2 minutes. Next, the 
mixture of reagent A & B was applied to the slides for 5 minutes; afterwards, DAB 
solution was placed on the slides for 10 minutes. Following the application of DAB, the 
slides were rinsed in distilled water for 1 minute and then dehydrated in 70%, 95%, and 
100% alcohols and xylene. Slides were mounted with Permount and stored at room 
temperature.  
Muscle Fiber Counting 
 Once the slides had been stained, they were observed under a microscope. Tissue 
samples were enlarged for proper viewing. Stained muscle fibers were counted, stained 
and unstained. The stained fibers were considered to be either fast or slow twitch 
depending on the stain used on the tissue sample slides; unstained fibers were considered 
to be any muscle fibers that did not take to the specific stain. These fiber counts were 
compared between normal and dwarf mice. Please see the results section for further 
information. 
Determining Cross-Sectional Muscle Area 
 Cross-sectional areas were measured using the software program, Scion. Ruler 
measurements were set at a known length of 1000 micrometers with .981 
pixels/micrometers being the measured distance. Stained muscle fiber images were 
analyzed using a freehand line drawing tool. Five cells were representative of the entire 
tissue sample and were measured twice for increased accuracy in the actual cross-
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sectional area of the muscle cell. The average of the 10 areas was used in the final t-test 
analysis. 
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CHAPTER IV 
RESULTS 
The following tables demonstrate the differences in muscle fiber counts: fast 
twitch versus slow twitch and average muscle fiber composition between wild type and 
dwarf mice. Comparisons can be seen across the lifespan in wild type and dwarf mice. 
Please see tables 1 through 6 for detailed information and the results section for further 
information regarding the laboratory observations. 
Wild type Mouse Muscle Fiber Counts 
Table 1: Muscle fiber counts for SOL in wild type mice. Fast vs. slow twitch. 
Animal #, 
Slide Section 
Age Fiber type 
stained 
Right vs. 
Left 
# of stained 
fibers 
# of fast 
unstained fibers 
Total # of 
cells 
N4 175 12 mo. Slow Right 143 
(55.85%) 
113 
(44.14%) 
256 
(100%) 
N4 176 12 mo. Fast Right 92 
(42.2%) 
126 
(57.8%) 
218 
(100%) 
N2 214 3 mo. Slow Left 204 
(58.45%) 
145 
(41.54%) 
349 
(100%) 
N2 213 3 mo. Fast Left 158 
(45.4%) 
190 
(54.6%) 
348 
(100%) 
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Dwarf Mouse Muscle Fiber Counts 
Table 2: Muscle fiber counts for SOL in Ames dwarf mice. Fast vs. slow twitch. 
Animal #, 
Slide 
Section 
Age Fiber type 
stained 
Right vs. 
left 
# of stained 
fibers 
# of 
unstained 
fibers 
Total # 
of cells 
D1 10x 6 mo. Fast Right 104 
(30.3%) 
239 
(69.7%) 
343 
(100%) 
D1 10x 6 mo. Slow Right 235 
(63.5%) 
135 
(36.5%) 
370 
(100%) 
D2 10x 6 mo. Fast Right 194 
(35.5%) 
352 
(64.5%) 
546 
(100%) 
D2 10x 6 mo. Slow Right 387 
(68.5%) 
178 
(31.5%) 
565 
(100%) 
 Comparisons between table 1 and 2 reveal composition differences in wild type 
and dwarf mice. As expected, the dwarf musculature has a higher percentage of slow 
twitch fibers. Although it is not a huge difference, the percentages do correlate with the 
normal percentage expected in both wild type and dwarf mice. The percentage of slow 
twitch fibers in SOL was 60-70% in dwarf compared to wild type of 50-60%.   
22 
 
Cross-sectional areas of soleus muscles in wild-type mice and Ames dwarf mice.  
Table 3: Cross-sectional areas for 12 month old, wild type mouse N4. Five different cells, 
representative of the entire tissue sample were measured twice for increased accuracy in 
actual area for muscle cells. Measurements are in micrometers. 
Sample 12 H&E R SOL N4 
Cell # Area 
Average Cross-sectional 
Muscle Area 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
2246 
2181 
3484 
3415 
1695 
1621 
1357 
1347 
3386 
3307
2403.9 
 
Table 4: Cross sectional area for 3 month old, wild-type mouse N2. Measurements are in 
micrometers. The bolded numbers are essential in the analysis for determining the cross-
sectional area of muscle fiber cells. 
Sample 3 H&E L SOL N2 
Cell # Area 
Average Cross-Sectional 
Muscle Area 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
2471.01 
2665.32 
2087.57 
2238.25 
3387.5 
3598.44 
2339.04 
2344.23 
2519.84 
2744.29
2639.55 
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Table 5: Cross sectional area for 6 month old, dwarf mouse, D1. Measurements are in 
micrometers. The bolded numbers are essential in the analysis of the cross-sectional area 
of the muscle fiber cells. 
Sample D1 SOL 10x H&E 
Cell # Area 
Average Cross-Sectional 
Muscle Area 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
808.43 
778.29 
484.23 
457.21 
659.84 
653.6 
871.81 
841.68 
814.66 
788.69
715.84 
 Comparing tables 3 and 4 show the mean cross-sectional area differences between 
the 3 month old  and 12 month old wild type mice were not significant (P=.478).  The 
average muscle area for the wild type 3 month old was 2639.55; the average muscle area 
for the 12 month old was 2403.9. However, differences were significant between dwarf 
and wild type cross-sectional areas (P<.001) with the dwarf mean area being about 25% 
the size of the wild type. The dwarf average muscle area was 715.84. This result was 
expected considering the smaller nature of the dwarf mouse. 
 Comparisons were drawn between the 3 month and 12 month normal mice and 
the 3 month normal mouse and the 3 month dwarf mouse. Using a two-tailed t-test 
analysis, the statistics for comparing the normal mice had a p value = 0.478, standard 
deviation of 905.05 for the 12 month old, standard deviation of 491.7 for the 3 month old, 
standard error of 286.2 for the 12 month old, and standard error of 155.5 for the 3 month 
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old. The preceding analysis may demonstrate the differences seen as a wild type mouse 
ages. The percentage of muscle fibers, specifically fast twitch fibers decreases; 
additionally, cross-sectional muscle areas in the SOL decrease as well. These results 
would be expected in a typical aging process of a wild type mouse.  
Comparisons between the 3 month old wild type mouse and 3 month old dwarf 
mouse were calculated using a two-tailed t-test analysis. Statistics demonstrated a p value 
of less than 0.0001. Standard deviation of 147.3 and standard error of 46.58 for the dwarf 
mouse and standard deviation of 491.7 and standard error of 155.5 for the wild type 
mouse was calculated.  
Conclusions that can be drawn from the comparison between the wild type and 
dwarf mice include a smaller cross-sectional muscle area in a dwarf mouse and no drastic 
change in the percentages of fast and slow twitch muscle fibers as the dwarf mouse ages. 
This is considered normal for a dwarf mouse; the percentage of fast twitch and slow 
twitch muscle fibers remain relatively constant as the mouse ages. Cross sectional muscle 
area was expected to be smaller in the dwarf mice considering their smaller size in 
comparison to the normal mice. Furthermore, it was also expected for there to be 
differences in fiber length and cross-sectional muscle area between wild type and dwarf 
mice.  
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CHAPTER V 
DISCUSSION 
 This study analyzed the counts of fast-twitch and slow-twitch muscle fibers and 
cross-sectional muscle fiber areas of tissue samples. It allowed the student researchers to 
perform microscopic surgery to remove the lower extremity musculature, obtain muscle 
tissue samples utilizing a Cryostat, prepare and stain tissue samples, and learn how to 
operate software programs to analyze results and draw comparisons. This study also 
demonstrated some main differences in muscle size and fiber composition between wild 
type and Ames dwarf mice. It revealed typically observed percentages of fast and slow 
twitch muscle fibers and muscle areas for the two mice samples. The wild type mice were 
expected to have a change in muscle fiber composition as they aged; additionally, an 
overall larger surface area in the lower extremity musculature was expected due to the 
bigger size of this mouse. In contrast, the dwarf mice did not demonstrate a significant 
change in muscle fiber composition as they aged and their muscle surface area was much 
smaller compared to the wild type mice.   
 Some limitations of the study include small sample size and younger age of the 
mice. All mice were between 3 months-12 months of age. Much of the specific aging 
processes could not be well observed in this study secondary to the age of the mice 
involved. Thus, conclusions on the aging process and sarcopenic effects in mouse 
musculature cannot be formulated. Furthermore, only one dwarf mouse soleus muscle’s 
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fiber composition was able to be analyzed due to the limited access of the software 
program and time constraints.  
Future studies should incorporate bigger sample sizes and newer software 
programs for analysis to determine actual muscle fiber composition changes and what 
those changes might indicate. Studies should also be performed on human subjects 
willing to undergo dietary restrictions and exercise protocol to determine if muscle fiber 
composition changes, or lack thereof, can be observed.  
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